|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Abciximab#Adult Indications and Dosage]] |
| {{Abciximab}}
| |
| {{CMG}}; {{AE}} {{SS}}, {{PB}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Abciximab is indicated as an adjunct to [[percutaneous coronary intervention]] for the prevention of cardiac ischemic complications.
| |
| | |
| * In patients undergoing [[percutaneous coronary intervention]]
| |
| * In patients with [[unstable angina]] not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
| |
| | |
| Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not been established.
| |
| | |
| Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3#nlm34067-9 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |